While healthy lifestyle changes greatly reduce the risk and prominence of CAD, it remains a significant medical challenge worldwide and is especially an issue in markets where persons with the disease may not have access to healthy lifestyle education or adequate healthcare.
Cardium’s focus is on providing Generx to individuals in international markets outside the United States. The therapeutic candidate is designed as an alternative for patients who may not be candidates for or who don’t have access to the costly and invasive surgical procedures such as coronary artery bypass surgery and angioplasty/stents. In the U.S., these procedures can cost a staggering $50,000-$100,000 over a five-year period following the initial treatment.
Generx is a regenerative medicine therapy that stimulates structural and physiological changes in the heart by promoting the growth of new collateral blood vessels following a significantly less invasive, one-time injection into the heart via standard cardiac infusion catheter. The candidate’s capability to elicit blood vessel growth greatly contrasts traditional drug therapies that provide relief for anginal chest pain without changing the underlying disease.
Cardium is conducting ASPIRE Phase 3 registration at leading cardiology centers in the Russian Federation to evaluate the therapeutic effects of Generx in patients with myocardial ischemia due to coronary artery disease.
For more information visit www.cardiumthx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
